|
Cenix BioScience Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery.
Dresden, Germany, February 2, 2009 - Cenix BioScience GmbH, a
leading RNA interference (RNAi)-focused contract research organization, today
announced that it has signed a research agreement to support Boehringer
Ingelheim in its ongoing efforts to discover novel therapeutic drug targets.
Cenix will apply its well-established expertise in combining high throughput
(HT) applications of RNAi-based gene silencing, the technology behind the 2006
Nobel Prize for Medicine, with high content phenotypic analyses in what will be
a genome-scale screen using cultured human cells. Multi-parametric
microscopy-based assays developed by Cenix using the Cellenger image analysis
platform from Munich-based Definiens, will be used to complement proprietary
assays developed at Boehringer Ingelheim, in order to generate detailed insights
into the cellular functions and loss-of-function phenotypes of analyzed genes.
“We have long been looking forward to this opportunity to combine our own
capabilities with those of our expert colleagues at Boehringer Ingelheim,” said
Dr. Christophe Echeverri, CEO/CSO of Cenix. “We expect that the excellent
complementarities between the two teams will deliver a particularly productive
and cost-effective driver for these programs.”
Such RNAi datasets, now
widely favored throughout the industry, offer a highly predictive and
cost-effective basis for mining the human genome to discover and prioritize
targets for therapeutic drug development in a wide range of disease fields. About Cenix BioScience GmbH
Now in its 10th year, Cenix BioScience has been the first and leading
contract research organization specialized in combining advanced applications of
RNA interference (RNAi) gene silencing with high content phenotypic analyses to
enhance and accelerate the discovery and pre-clinical development of novel
therapeutics. Cenix has built-up a solid track record, successfully advancing
therapeutic programs for numerous major industry and academic partners by
addressing the specific needs of each through fully-customized, cutting-edge
research offerings covering a wide range of disease fields. The well-established
core capabilities in high throughput RNAi and multi-parametric microscopy assays
have yielded optimized protocols in a broad and ever-growing collection of
cultured cell models, and are now complemented by microRNA-focused
experimentation and in vivo applications of synthetic siRNAs. As such, Cenix is
a mature and fully-proven industrial research partner, applying the highest of
scientific best practices and offering a breadth and depth of expertise second
to none world wide. Please contact Cenix or visit the company’s web site
www.cenix-bioscience.com for more information.
Cenix and the Cenix BioScience logo are registered
trademarks owned by Cenix BioScience GmbH in the US and other countries.
Cellenger and Definiens are registered trademarks owned by Definiens GmbH.
|
